Findings

What do systematic reviews say?

107 questions · 109 findings · 12 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 8.3%GRADE not reported 0 · 0%Very low 28 · 25.7%Low 40 · 36.7%Moderate 20 · 18.3%High 12 · 11%

Omega‐3 vs placebo

Overall dementia severity (cognition and function combined) · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 542 participants
High

Omega‐3 vs placebo

Memory ‐ not measured · Apathy in people with mild‐to‐moderate Alzheimer's disease

The review found no eligible studies for this question.

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease

Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
RR 1.05 [0.78, 1.41]
1 study · 402 participants
High

Omega‐3 vs placebo

QoL · Apathy in people with mild‐to‐moderate Alzheimer's disease

2 findings from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 269 participants
Moderate
Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 332 participants
High

Omega‐3 vs placebo

Depressive symptoms · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 178 participants
High

Omega‐3 vs placebo

Mental health outcomes · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 543 participants
High

Omega‐3 vs placebo

Cognitive function · Apathy in people with mild‐to‐moderate Alzheimer's disease

2 findings from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 566 participants
High
Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 202 participants
High

Omega‐3 vs placebo

IADL · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Moderate

LCPUFA supplemented formula vs control formula

Visual acuity · term infants

LCPUFA supplemented formula showed no clear difference in visual acuity/Teller cards at 12 months (cycles/degree) ‐ DHA and AA… compared with control formula (low certainty).

1 finding from 1 review

Long chain polyunsaturated fatty acid supplementation in infants born at term 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 256 participants
Low

LCPUFA supplemented formula vs control formula

Sweep VEP acuity at 12 months (LogMAR) ‐ DHA and AA vs normal term formula · term infants

LCPUFA supplemented formula showed no clear difference in sweep VEP acuity at 12 months (LogMAR) ‐ DHA and AA vs normal term… compared with control formula (low certainty).

1 finding from 1 review

Long chain polyunsaturated fatty acid supplementation in infants born at term 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 244 participants
Low

LCPUFA supplemented formula vs control formula

MDI scores (Bayley) at 18 months ‐ DHA and AA vs normal term formula · term infants

LCPUFA supplemented formula showed no clear difference in MDI scores (Bayley) at 18 months ‐ DHA and AA vs normal term formula compared with control formula (low certainty).

1 finding from 1 review

Long chain polyunsaturated fatty acid supplementation in infants born at term 2017 · Cochrane Headline outcomes only
MD 0.06
4 studies · 661 participants
Low

LCPUFA supplemented formula vs control formula

PDI scores (Bayley) at 18 months ‐ DHA and AA vs normal term formula · term infants

LCPUFA supplemented formula showed no clear difference in PDI scores (Bayley) at 18 months ‐ DHA and AA vs normal term formula compared with control formula (low certainty).

1 finding from 1 review

Long chain polyunsaturated fatty acid supplementation in infants born at term 2017 · Cochrane Headline outcomes only
MD 0.69
4 studies · 661 participants
Low

LCPUFA supplemented formula vs control formula

Weight (z score) · term infants

LCPUFA supplemented formula showed no clear difference in weight at 12 months (z scores) ‐ DHA and AA vs normal term formula compared with control formula (low certainty).

1 finding from 1 review

Long chain polyunsaturated fatty acid supplementation in infants born at term 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 521 participants
Low

LCPUFA supplemented formula vs control formula

Length (cm) · term infants

LCPUFA supplemented formula showed no clear difference in length at 12 months (z scores) ‐ DHA and AA vs normal term formula compared with control formula (low certainty).

1 finding from 1 review

Long chain polyunsaturated fatty acid supplementation in infants born at term 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 521 participants
Low

LCPUFA supplemented formula vs control formula

Head circumference at 12 months (z scores) ‐ DHA and AA vs normal term formula · term infants

LCPUFA supplemented formula showed no clear difference in head circumference at 12 months (z scores) ‐ DHA and AA vs normal… compared with control formula (low certainty).

1 finding from 1 review

Long chain polyunsaturated fatty acid supplementation in infants born at term 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 464 participants
Low

PUFA vs monounsaturated fatty acid (MUFA)

Relapse · people with multiple sclerosis

It is very uncertain whether polyunsaturated fatty acid (PUFA) changes relapse(assessed as number of participants experiencing relapse) compared with monounsaturated fatty acid (MUFA) (very low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 1.02 [0.88, 1.2]
3 studies · 217 participants
Very low

PUFA vs monounsaturated fatty acid (MUFA)

Change in validated disability scale ( · people with multiple sclerosis

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 102 participants
Very low

PUFA vs monounsaturated fatty acid (MUFA)

Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis

Polyunsaturated fatty acid (PUFA) showed no clear difference in global impression of deterioration (investigator defined global… compared with monounsaturated fatty acid (MUFA) (low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 0.85 [0.71, 1.03]
4 studies · 542 participants
Low

PUFA vs monounsaturated fatty acid (MUFA)

MRI activity ‐ not measured · people with multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PUFA vs monounsaturated fatty acid (MUFA)

SAEs · people with multiple sclerosis

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low